Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PRSNQ: BK PLAN effective. All shares cancelled:
http://otce.finra.org/DLDeletions
PRSNQ: Perseon Corporation changed to BSD Med Corp.:
http://otce.finra.org/DLSymbolNameChanges
PRSN: effective June 2,2016 PRSN will change to PRSNQ, bankruptcy:
http://otce.finra.org/DLSymbolNameChanges
Mayerxx, could you e-mail me at alectric@yahoo.com? That response from IR was clearly fraudulent given the 8-K filed yesterday at http://www.sec.gov/Archives/edgar/data/320174/000091228216000671/perseon8k_033016.htm. I am in touch with the attorney handling the lawsuit and can give you his e-mail address where you may forward that response. Shareholders need to hold management accountable. Thanks.
Thanks, mayerxx, I tried that link, but never received a response. Who was it that wrote you from IR? Also, do you know anyone from Salt Lake who can stop by to see if anyone is there?
Mayerxx, how were you able to contact IR? I tried to get through to Perseon on their website, wondering what the status is on the Terumo agreement, but have not heard anything from them. The last I heard, they were exploring strategic options. If you try to call them, you'll find nobody answers the phone. You get a voicemail greeting no matter who you try to reach. Someone by the name of "Dave".
got an email back today from IR and they said they said "our team is working on exciting projects and new developments and are looking forward to providing the details in the near future"
They are not being "lent" the 1 million. They sold shares of another company that they owned. I'm guessing they asked if they can sell them all at once, and the only reason they were allowed to do it was if they forfeited future royalties.
I just dont understand warrants, what is PRSNW?
If they plan on selling they will find another buyer soon. If they are raising money they must have a plan or no one would lend them anything.
Float is only 9 million shares and there is no dilution. Patience will pay here
That's what has me intrigued here....I mean it went from ~80 cents down to 20 cents and then plateaued for a while and then down to these levels. All basically because of the 12/22 announcement of the expired buyout deal.
Those deals happen quite often, sometiems they are quite substantial and sometimes they are not.
I dont see why this doesnt have the potential to get back to that .20 shelf, and even better back to the .80 levels.
We know from the 2/26 8-k that they are raising money, the question is what are they going to do with that money. Take a trip to the bahamas and put this to bed, or do they have a plan and are just waiting to let everybody know.
Seems very low risk/high reward right now.
At the end of the day they were able to sell offered shares @.99 which is great
The 8-K to me appears to be an effort to raise money, and in such forfeiting future royalties....so a grab money quick. Now will they use that money for business ventures or just stuff in their own pockets. The other form on 2/26 is the one that has me perplexed, 13 million outstanding warrants at .99/share? Not sure what that means.
Any idea what the new 8k means?
That's what this money PIT gets!!! Garbage = GARBAGE!!!
PRSN delisted from the Nasdaq to the OTC.:
http://otce.finra.org/DLAdditions
1 dollar, I like that!
below 0.1$ ...mmmmm
PRSN is way way oversold. Bounce us imminent
PERSEON new filings as of 1/11/2016:
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard. Compensatory Arrangements of Certain Officers (CEO)
http://investor.perseonmedical.com/phoenix.zhtml?c=75162&p=irol-SECText&TEXT=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9maWxpbmcueG1sP2lwYWdlPTEwNjY3MzcwJkRTRVE9MCZTRVE9MCZTUURFU0M9U0VDVElPTl9FTlRJUkUmc3Vic2lkPTU3
13,225,000 shares of Common Stock issuable upon the exercise of the 13,225,000 outstanding Warrants issued
in our public offering
http://investor.perseonmedical.com/phoenix.zhtml?c=75162&p=irol-SECText&TEXT=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9maWxpbmcueG1sP2lwYWdlPTEwNjY3Mzg0JkRTRVE9MCZTRVE9MCZTUURFU0M9U0VDVElPTl9FTlRJUkUmc3Vic2lkPTU3
very low pps now
Recent 8K "Company was experiencing serious liquidity problems and that it was unable to raise additional capital to finance .... Company terminated a substantial number of employees"
Ex-employees are selling their shares.
Why the big drop?
Dropping hard today.
Might see PRSN at a dime.
No bounce,they will be bankrupt soon.
Watching for bounce tomorrow ~
Agreed. A little overdone to the downside perhaps.
Ughhh guess this one failed!!!
$PRSN ~ Perseon Corporation due diligence report
$PRSN recent news/filings
## source: finance.yahoo.com
Tue, 22 Dec 2015 15:00:00 GMT ~ 10:00 am Perseon: Galil Medical confirms the expiration of its offer to acquire Perseon, and the termination of their merger agreement
read full: http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#prsn
*********************************************************
Tue, 22 Dec 2015 14:57:00 GMT ~ Galil Medical Tender Offer to Acquire Perseon Corporation Expires
[PR Newswire] - PRSNW) common stock for $1.00 per share in cash and (ii) all of the outstanding publicly traded warrants to purchase Perseon common stock for $0.02 per warrant (the "Offer"). The Offer expired immediately after 11:59 p.m., Eastern Time, on December 21, 2015. The Depositary for the Offer has informed Galil that as of the expiration of the Offer, approximately 6,263,504 shares of common stock of Perseon have been validly tendered and not properly withdrawn pursuant to the Offer, representing approximately 64% of Perseon's common stock.
read full: http://finance.yahoo.com/news/galil-medical-tender-offer-acquire-145700011.html
*********************************************************
Tue, 22 Dec 2015 12:21:52 GMT ~ PERSEON CORP Files SEC form 8-K, Termination of a Material Definitive Agreement
read full: http://biz.yahoo.com/e/151222/prsn8-k.html
*********************************************************
Fri, 18 Dec 2015 12:11:00 GMT ~ 4 Stocks Under $10 Making Big Moves
read full: http://www.thestreet.com/story/13402238/1/4-stocks-under-10-making-big-moves.html?puc=yahoo&cm_ven=YAHOO
*********************************************************
Thu, 10 Dec 2015 10:33:24 GMT ~ Galil Medical and Perseon Corporation Announce Tender Offer/Merger Information Call
[at noodls] - Conference Call and Webcast Scheduled for Wednesday, December 2 at 11:00 a.m. Eastern Time/9:00 a.m. Mountain Time ARDEN HILLS, Minn. and SALT LAKE CITY, Nov. 30, 2015 (GLOBE NEWSWIRE) -- Galil Medical ...
read full: http://www.noodls.com/view/5D2872033B6D7BC0D0342EB093E3879A957E92C1
*********************************************************
$PRSN charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$PRSN company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/PRSN/company-info
Ticker: $PRSN
OTC Market Place: Not Available
CIK code: 0000320174
Company name: Perseon Corporation
Company website: http://www.bsdmc.com
Incorporated In: DE, USA
Business Description: OTC Markets | Official site of the OTCQX, OTCQB and OTC Pink Marketplaces featuring Free Stock & Bond Quotes, Trade Prices, Chart, Financials and Company News & Information for Investors, Companies and Traders - OTCMarkets.com (window.NREUM||(NREUM={})).loader_config={xpid:"UwMGWVdSGwQIU1RQAgQ="};window.NREUM||(NREUM={}),__nr_require=function(t,e,n){function r(n){if(!e[n]){var o=e[n]={exports:{}};t[n][0].call(o.exports,function(e){var o=t[n][1][e];return r(o||e)},o,o.exports)}return e[n].exports}if("function"==typeof __nr_require)return __nr_require;for(var o=0;od;d++)c[d].apply(u,n);return u}function a(t,e){f[t]=s(t).concat(e)}function s(t){return f[t]||[]}function c(){return n(e)}var f={};return{on:a,emit:e,create:c,listeners:s,_events:f}}function r(){return{}}var o="nr@context",i=t("gos");e.exports=n()},{gos:"7eSDFh"}],ee:[function(t,e){e.exports=t("QJf3ax")},{}],3:[function(t){function e(t){try{i.console&&console.log(t)}catch(e){}}var n,r=t("ee"),o=t(1),i={};try{n=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(i.console=!0,-1!==n.indexOf("dev")&&(i.dev=!0),-1!==n.indexOf("nr_dev")&&(i.nrDev=!0))}catch(a){}i.nrDev&&r.on("internal-error",function(t){e(t.stack)}),i.dev&&r.on("fn-err",function(t,n,r){e(r.stack)}),i.dev&&(e("NR AGENT IN DEVELOPMENT MODE"),e("flags: "+o(i,function(t){return t}).join(", ")))},{1:24,ee:"QJf3ax"}],4:[function(t){function e(t,e,n,i,s){try{c?c-=1:r("err",[s||new UncaughtException(t,e,n)])}catch(f){try{r("ierr",[f,(new Date).getTime(),!0])}catch(u){}}return"function"==typeof a?a.apply(this,o(arguments)):!1}function UncaughtException(t,e,n){this.message=t||"Uncaught error with no additional information",this.sourceURL=e,this.line=n}function n(t){r("err",[t,(new Date).getTime()])}var r=t("handle"),o=t(6),i=t("ee"),a=window.onerror,s=!1,c=0;t("loader").features.err=!0,t(5),window.onerror=e;try{throw new Error}catch(f){"stack"in f&&(t(1),t(2),"addEventListener"in window&&t(3),window.XMLHttpRequest&&XMLHttpRequest.prototype&&XMLHttpRequest.prototype.addEventListener&&window.XMLHttpRequest&&XMLHttpRequest.prototype&&XMLHttpRequest.prototype.addEventListener&&!/CriOS/.test(navigator.userAgent)&&t(4),s=!0)}i.on("fn-start",function(){s&&(c+=1)}),i.on("fn-err",function(t,e,r){s&&(this.thrown=!0,n(r))}),i.on("fn-end",function(){s&&!this.thrown&&c>0&&(c-=1)}),i.on("internal-error",function(t){r("ierr",[t,(new Date).getTime(),!0])})},{1:11,2:10,3:8,4:12,5:3,6:25,ee:"QJf3ax",handle:"D5DuLP",loader:"G9z0Bl"}],5:[function(t){if(window.addEventListener){var e=t("handle"),n=t("ee");t(1),window.addEventListener("click",function(){e("inc",["ck"])},!1),window.addEventListener("hashchange",function(){e("inc",["hc"])},!1),n.on("pushState-start",function(){e("inc",["ps"])})}},{1:9,ee:"QJf3ax",handle:"D5DuLP"}],6:[function(t){t("loader").features.ins=!0},{loader:"G9z0Bl"}],7:[function(t){function e(){}if(window.performance&&window.performance.timing&&window.performance.getEntriesByType){var n=t("ee"),r=t("handle"),o=t(1),i=t(2);t("loader").features.stn=!0,t(3);var a=Event;n.on("fn-start",function(t){var e=t[0];e instanceof a&&(this.bstStart=Date.now())}),n.on("fn-end",function(t,e){var n=t[0];n instanceof a&&r("bst",[n,e,this.bstStart,Date.now()])}),o.on("fn-start",function(t,e,n){this.bstStart=Date.now(),this.bstType=n}),o.on("fn-end",function(t,e){r("bstTimer",[e,this.bstStart,Date.now(),this.bstType])}),i.on("fn-start",function(){this.bstStart=Date.now()}),i.on("fn-end",function(t,e){r("bstTimer",[e,this.bstStart,Date.now(),"requestAnimationFrame"])}),n.on("pushState-start",function(){this.time=Date.now(),this.startPath=location.pathname+location.hash}),n.on("pushState-end",function(){r("bstHist",[location.pathname+location.hash,this.startPath,this.time])}),"addEventListener"in window.performance&&(window.performance.addEventListener("webkitresourcetimingbufferfull",function(){r("bstResource",[window.performance.getEntriesByType("resource")]),window.performance.webkitClearResourceTimings()},!1),window.performance.addEventListener("resourcetimingbufferfull",function(){r("bstResource",[window.performance.getEntriesByType("resource")]),window.performance.clearResourceTimings()},!1)),document.addEventListener("scroll",e,!1),document.addEventListener("keypress",e,!1),document.addEventListener("click",e,!1)}},{1:11,2:10,3:9,ee:"QJf3ax",handle:"D5DuLP",loader:"G9z0Bl"}],8:[function(t,e){function n(t){i.inPlace(t,["addEventListener","removeEventListener"],"-",r)}function r(t){return t[1]}var o=t("ee").create(),i=t(1)(o),a=t("gos");if(e.exports=o,n(window),"getPrototypeOf"in Object){for(var s=document;s&&!s.hasOwnProperty("addEventListener");)s=Object.getPrototypeOf(s);s&&n(s);for(var c=XMLHttpRequest.prototype;c&&!c.hasOwnProperty("addEventListener");)c=Object.getPrototypeOf(c);c&&n(c)}else XMLHttpRequest.prototype.hasOwnProperty("addEventListener")&&n(XMLHttpRequest.prototype);o.on("addEventListener-start",function(t,e){function n(){return s}if(t[1]){var r=t[1];if("function"==typeof r){var s=a(r,"nr@wrapped",function(){return i(r,"fn-",n,r.name||"anonymous")});this.wrapped=t[1]=s,o.emit("initEventContext",[t,e],this.wrapped)}else"function"==typeof r.handleEvent&&i.inPlace(r,["handleEvent"],"fn-")}}),o.on("removeEventListener-start",function(t){var e=this.wrapped;e&&(t[1]=e)})},{1:26,ee:"QJf3ax",gos:"7eSDFh"}],9:[function(t,e){var n=t("ee").create(),r=t(1)(n);e.exports=n,r.inPlace(window.history,["pushState","replaceState"],"-")},{1:26,ee:"QJf3ax"}],10:[function(t,e){var n=t("ee").create(),r=t(1)(n);e.exports=n,r.inPlace(window,["requestAnimationFrame","mozRequestAnimationFrame","webkitRequestAnimationFrame","msRequestAnimationFrame"],"raf-"),n.on("raf-start",function(t){t[0]=r(t[0],"fn-")})},{1:26,ee:"QJf3ax"}],11:[function(t,e){function n(t,e,n){t[0]=i(t[0],"fn-",null,n)}function r(t,e,n){function r(){return a}this.ctx={};var a={"nr@context":this.ctx};o.emit("initTimerContext",[t,n],a),t[0]=i(t[0],"fn-",r,n)}var o=t("ee").create(),i=t(1)(o);e.exports=o,i.inPlace(window,["setTimeout","setImmediate"],"setTimer-"),i.inPlace(window,["setInterval"],"setInterval-"),i.inPlace(window,["clearTimeout","clearImmediate"],"clearTimeout-"),o.on("setInterval-start",n),o.on("setTimer-start",r)},{1:26,ee:"QJf3ax"}],12:[function(t,e){function n(){f.inPlace(this,p,"fn-",o)}function r(t,e){f.inPlace(e,["onreadystatechange"],"fn-")}function o(t,e){return e}function i(t,e){for(var n in t)e[n]=t[n];return e}var a=t("ee").create(),s=t(1),c=t(2),f=c(a),u=c(s),d=window.XMLHttpRequest,p=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"];e.exports=a,window.XMLHttpRequest=function(t){var e=new d(t);try{a.emit("new-xhr",[],e),e.hasOwnProperty("addEventListener")&&u.inPlace(e,["addEventListener","removeEventListener"],"-",o),e.addEventListener("readystatechange",n,!1)}catch(r){try{a.emit("internal-error",[r])}catch(i){}}return e},i(d,XMLHttpRequest),XMLHttpRequest.prototype=d.prototype,f.inPlace(XMLHttpRequest.prototype,["open","send"],"-xhr-",o),a.on("send-xhr-start",r),a.on("open-xhr-start",r)},{1:8,2:26,ee:"QJf3ax"}],13:[function(t){function e(t){var e=this.params,r=this.metrics;if(!this.ended){this.ended=!0;for(var i=0;c>i;i++)t.removeEventListener(s,this.listener,!1);if(!e.aborted){if(r.duration=(new Date).getTime()-this.startTime,4===t.readyState){e.status=t.status;var a=t.responseType,f="arraybuffer"===a||"blob"===a||"json"===a?t.response:t.responseText,u=n(f);if(u&&(r.rxSize=u),this.sameOrigin){var d=t.getResponseHeader("X-NewRelic-App-Data");d&&(e.cat=d.split(", ").pop())}}else e.status=0;r.cbTime=this.cbTime,o("xhr",[e,r,this.startTime])}}}function n(t){if("string"==typeof t&&t.length)return t.length;if("object"!=typeof t)return void 0;if("undefined"!=typeof ArrayBuffer&&t instanceof ArrayBuffer&&t.byteLength)return t.byteLength;if("undefined"!=typeof Blob&&t instanceof Blob&&t.size)return t.size;if("undefined"!=typeof FormData&&t instanceof FormData)return void 0;try{return JSON.stringify(t).length}catch(e){return void 0}}function r(t,e){var n=i(e),r=t.params;r.host=n.hostname+":"+n.port,r.pathname=n.pathname,t.sameOrigin=n.sameOrigin}if(window.XMLHttpRequest&&XMLHttpRequest.prototype&&XMLHttpRequest.prototype.addEventListener&&!/CriOS/.test(navigator.userAgent)){t("loader").features.xhr=!0;var o=t("handle"),i=t(2),a=t("ee"),s=["load","error","abort","timeout"],c=s.length,f=t(1),u=window.XMLHttpRequest;t(4),t(3),a.on("new-xhr",function(){this.totalCbs=0,this.called=0,this.cbTime=0,this.end=e,this.ended=!1,this.xhrGuids={}}),a.on("open-xhr-start",function(t){this.params={method:t[0]},r(this,t[1]),this.metrics={}}),a.on("open-xhr-end",function(t,e){"loader_config"in NREUM&&"xpid"in NREUM.loader_config&&this.sameOrigin&&e.setRequestHeader("X-NewRelic-ID",NREUM.loader_config.xpid)}),a.on("send-xhr-start",function(t,e){var r=this.metrics,o=t[0],i=this;if(r&&o){var f=n(o);f&&(r.txSize=f)}this.startTime=(new Date).getTime(),this.listener=function(t){try{"abort"===t.type&&(i.params.aborted=!0),("load"!==t.type||i.called===i.totalCbs&&(i.onloadCalled||"function"!=typeof e.onload))&&i.end(e)}catch(n){try{a.emit("internal-error",[n])}catch(r){}}};for(var u=0;c>u;u++)e.addEventListener(s,this.listener,!1)}),a.on("xhr-cb-time",function(t,e,n){this.cbTime+=t,e?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof n.onload||this.end(n)}),a.on("xhr-load-added",function(t,e){var n=""+f(t)+!!e;this.xhrGuids&&!this.xhrGuids[n]&&(this.xhrGuids[n]=!0,this.totalCbs+=1)}),a.on("xhr-load-removed",function(t,e){var n=""+f(t)+!!e;this.xhrGuids&&this.xhrGuids[n]&&(delete this.xhrGuids[n],this.totalCbs-=1)}),a.on("addEventListener-end",function(t,e){e instanceof u&&"load"===t[0]&&a.emit("xhr-load-added",[t[1],t[2]],e)}),a.on("removeEventListener-end",function(t,e){e instanceof u&&"load"===t[0]&&a.emit("xhr-load-removed",[t[1],t[2]],e)}),a.on("fn-start",function(t,e,n){e instanceof u&&("onload"===n&&(this.onload=!0),("load"===(t[0]&&t[0].type)||this.onload)&&(this.xhrCbStart=(new Date).getTime()))}),a.on("fn-end",function(t,e){this.xhrCbStart&&a.emit("xhr-cb-time",[(new Date).getTime()-this.xhrCbStart,this.onload,e],e)})}},{1:"XL7HBI",2:14,3:12,4:8,ee:"QJf3ax",handle:"D5DuLP",loader:"G9z0Bl"}],14:[function(t,e){e.exports=function(t){var e=document.createElement("a"),n=window.location,r={};e.href=t,r.port=e.port;var o=e.href.split("://");return!r.port&&o[1]&&(r.port=o[1].split("/")[0].split("@").pop().split(":")[1]),r.port&&"0"!==r.port||(r.port="https"===o[0]?"443":"80"),r.hostname=e.hostname||n.hostname,r.pathname=e.pathname,r.protocol=o[0],"/"!==r.pathname.charAt(0)&&(r.pathname="/"+r.pathname),r.sameOrigin=!e.hostname||e.hostname===document.domain&&e.port===n.port&&e.protocol===n.protocol,r}},{}],15:[function(t,e){function n(t){return function(){r(t,[(new Date).getTime()].concat(i(arguments)))}}var r=t("handle"),o=t(1),i=t(2);"undefined"==typeof window.newrelic&&(newrelic=window.NREUM);var a=["setPageViewName","addPageAction","setCustomAttribute","finished","addToTrace","inlineHit","noticeError"];o(a,function(t,e){window.NREUM[e]=n("api-"+e)}),e.exports=window.NREUM},{1:24,2:25,handle:"D5DuLP"}],gos:[function(t,e){e.exports=t("7eSDFh")},{}],"7eSDFh":[function(t,e){function n(t,e,n){if(r.call(t,e))return t[e];var o=n();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(t,e,{value:o,writable:!0,enumerable:!1}),o}catch(i){}return t[e]=o,o}var r=Object.prototype.hasOwnProperty;e.exports=n},{}],D5DuLP:[function(t,e){function n(t,e,n){return r.listeners(t).length?r.emit(t,e,n):void(r.q&&(r.q[t]||(r.q[t]=[]),r.q[t].push(e)))}var r=t("ee").create();e.exports=n,n.ee=r,r.q={}},{ee:"QJf3ax"}],handle:[function(t,e){e.exports=t("D5DuLP")},{}],XL7HBI:[function(t,e){function n(t){var e=typeof t;return!t||"object"!==e&&"function"!==e?-1:t===window?0:i(t,o,function(){return r++})}var r=1,o="nr@id",i=t("gos");e.exports=n},{gos:"7eSDFh"}],id:[function(t,e){e.exports=t("XL7HBI")},{}],G9z0Bl:[function(t,e){function n(){var t=p.info=NREUM.info,e=f.getElementsByTagName("script")[0];if(t&&t.licenseKey&&t.applicationID&&e){s(d,function(e,n){e in t||(t[e]=n)});var n="https"===u.split(":")[0]||t.sslForHttp;p.proto=n?"https://":"http://",a("mark",["onload",i()]);var r=f.createElement("script");r.src=p.proto+t.agent,e.parentNode.insertBefore(r,e)}}function r(){"complete"===f.readyState&&o()}function o(){a("mark",["domContent",i()])}function i(){return(new Date).getTime()}var a=t("handle"),s=t(1),c=window,f=c.document;t(2);var u=(""+location).split("?")[0],d={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",agent:"js-agent.newrelic.com/nr-768.min.js"},p=e.exports={offset:i(),origin:u,features:{}};f.addEventListener?(f.addEventListener("DOMContentLoaded",o,!1),c.addEventListener("load",n,!1)):(f.attachEvent("onreadystatechange",r),c.attachEvent("onload",n)),a("mark",["firstbyte",i()])},{1:24,2:15,handle:"D5DuLP"}],loader:[function(t,e){e.exports=t("G9z0Bl")},{}],24:[function(t,e){function n(t,e){var n=[],o="",i=0;for(o in t)r.call(t,o)&&(n=e(o,t[o]),i+=1);return n}var r=Object.prototype.hasOwnProperty;e.exports=n},{}],25:[function(t,e){function n(t,e,n){e||(e=0),"undefined"==typeof n&&(n=t?t.length:0);for(var r=-1,o=n-e||0,i=Array(0>o?0:o);++r
$PRSN share structure
## source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: 9,766,323 a/o Oct 26, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$PRSN extra dd links
Company name: Perseon Corporation
Company website: http://www.bsdmc.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/PRSN/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/PRSN/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=PRSN+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=PRSN+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=PRSN+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/PRSN/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/PRSN/news - http://finance.yahoo.com/q/h?s=PRSN+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/PRSN/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/PRSN/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/PRSN/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/PRSN/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/PRSN/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/PRSN/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/PRSN/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/PRSN/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=PRSN+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/PRSN
DTCC (dtcc.com): http://search2.dtcc.com/?q=Perseon+Corporation&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Perseon+Corporation
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Perseon+Corporation&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.bsdmc.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.bsdmc.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.bsdmc.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/PRSN/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/PRSN
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/PRSN/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/PRSN/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/PRSN/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000320174&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/PRSN/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/PRSN/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/PRSN/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/PRSN/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=PRSN&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=PRSN
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/PRSN/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=PRSN+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=PRSN+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=PRSN
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=PRSN
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=PRSN+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/PRSN/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=PRSN+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/PRSN.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=PRSN
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/PRSN/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/PRSN/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/PRSN/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/PRSN/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/PRSN
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/PRSN
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/PRSN:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=PRSN
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=PRSN
Looks like shorts working overtime ha
Bullish inverted hammer :)
Jmo ;)
Well you were right...
They couldn't come up with the money.
There also were not enough of the public warrants tendered...
But the bottom line is, the merger would have terminated anyway
because they did not secure the financing.
Next stop bankruptcy...
I wonder if galil will buy the assets they wanted for pennies rather than a dollar
when the company is dissolved?
If you're in why would you run scared now? Take the dollar! Duh
Extension of the offer expiration date from Perseon Form SC TO/T-A:
"All references to “11:59 PM, New York City Time, on December 7, 2015” as the “Expiration Date” are hereby amended to refer to “11:59 PM, New York City Time, on December 21, 2015”."
From Galil PR:
Galil Medical Extends Tender Offer Period to Acquire Perseon Corporation
Arden Hills, MN, and Salt Lake City, UT– December 2, 2015 – Galil Medical Ltd. ('Galil"), a global leader in delivering innovative cryotherapy ablation solutions, today announced Galil's indirect wholly owned subsidiary Galil Merger Sub, Inc. has extended its previously announced tender offer to purchase (i) all of the outstanding publicly traded shares of Perseon Corporation (NASDAQ: PRSN; PRSNW) common stock for $1.00 per share in cash, and (ii) all of the outstanding publicly traded warrants to purchase Perseon common stock for $0.02 per warrant (the "Offer"). The Offer will now expire immediately after 11:59 p.m., Eastern Time, on December 21, 2015, unless it is further extended. All other terms and conditions of the Offer remain unchanged.
Tomorrow 11:30 conference call about the buyout!!!
Here comes a dollar!!!!!!
Big day today,don't get the sudden move up.Was there news today?Maybe tomorrow.
PRSN nice close
HOUSTON! WE HAVE LIFT~OFF!!
PRSN~ LOOKING GREAT HERE! Bouncing off the 20MA with a Green Candle.. Nice!
Can you share the details of this "sordid past"?
I am well aware of this
http://www.law360.com/articles/107809/galil-sues-healthtronics-in-endocare-merger-spat
This seems like it was more Endo's fault; but I have not read the docs on PACER yet...
I have more faith in privately held companies than these scammy penny stock companies...
:)
ENDO was on the nasdaq...so was HTRN...
but it does not seem like things went so well for HTRN...
http://www.sec.gov/Archives/edgar/data/1018871/000119312510157456/d8k.htm
I hear you, Galil has a sordid past with mergers. 26 million is a lot to raise. I seriously doubt they will be able to do it but I sincerely hope they do for shareholders here.
Followers
|
32
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1350
|
Created
|
10/14/03
|
Type
|
Free
|
Moderators |
Physicians who need to ablate soft tissue tumors, both malignant and benign, prefer the MicroThermX microwave ablation system because its 915 MHz frequency results in a deeper penetration into the tissue.Physicians get more power and, at the same time, more control when removing tumors in organs such as lung, liver, and kidney.
When larger ablation zones are required physicians rely on the Synchronous Wave Alignment technology of MicroThermX. Using multiple Perseon antenna tips increases the probability of reaching the center of large tumors and creating larger margins to ensure that all of the surrounding cells are eliminated.
Due to the flexibility of the system physicians use MicroThermX in open surgical procedures and percutaneous ablations. It consists of a single generator and amplifier that deliver microwave energy to single or multiple antenna(s).
The system is not intended for use in cardiac procedures. It is contraindicated in patients with pacemakers or other active electronic device implants and in pregnant women.
"With Perseon, you get a much bigger and better burn in a shorter amount of time."
— Dr. Sohail Contractor, Section Chief, Interventional Radiology Rutgers New Jersey Medical School
Microwave coagulation applicator and system patent.
https://www.google.ca/patents/US8414570.
The company owns eight non-expired patents in the United States related to certain components or technology of its ablation and hyperthermia systems. The company has one patent license from Duke University. 11 new U.S. patent applications have been published in the United States, and 1 foreign patent is issued and others are pending. A total of 29 U.S. patents have been issued to the company. Government Regulation The company’s products sold in the United States are subject to the Federal Food, Drug, and Cosmetic Act (FDCA), as implemented and enforced by the FDA. Certain of the company’s products sold in the United States require FDA clearance to market under Section 510(k) of the FDCA. History The company was incorporated under the laws of the state of Utah in 1978 and was reincorporated in the state of Delaware in 1986. It was formerly known as BSD Medical Corporation and changed its name to Perseon Corporation in 2015.
Perseon CEO Carnell on righting the ship in medtech: http://www.massdevice.com/perseon-ceo-carnell-on-righting-the-ship-in-medtech/
AUGUST 20, 2015 BY FINK DENSFORD
"Perseon LogoPerseon (NSDQ:PRSN), previously known as BSD Medical, has gone through some significant changes in the past year – renamed, rebranded, and divested of assets. At the helm for these changes is Clint Carnell, former CEO of MyoScience, advisor to Covidienand veep of sales at Bausch & Lomb’s surgical division.
Carnell has been in the medical device industry for more than 20 years, and spoke to MassDevice.com about his transition to Perseon earlier this year, how he’s helping the company turn around and how and why he operates within the medical device industry.
Perseon's Clint Carnell
Carnell “There’s nothing like being in medical devices – you’re working on something with smart people, engineers, scientists, physicians. You’re really solving complex problems, you’re developing products that are quite sophisticated and applying them to life saving benefits,” Carnell told MassDevice.com in an interview.
When he joined Perseon, Carnell said the company needed help. It had an incredibly useful device in its microwave ablation technology, but was burdened and on a sliding trajectory.
“I’m comfortable coming into companies that have had troubles – identifying problems, creating critical solutions and hiring and inspiring a team to fix them,” Carnell said.
He did just that, taking steps to divest the company of its hyperthermia devision, reshaped the board and leadership teams and tried to focus the company on commercializing what he saw as a device that could become a standard of care in the field.
Perseon’s flagship product is the MicroThermX, a microwave ablation system used to ablate soft tissue tumors. The device can be used in percutaneous or open surgical procedures, and received expanded 510(k) clearance earlier this year for laproscopic ablation procedures using image guidance.
The novel product is used to treat cancer, which Carnell said only reinforced the importance of what he does and why he stays in the medical device industry.
“In the case of Perseon, I don’t think there’s a more noble cause than going to work every day trying to fight one of humanity’s worst diseases, and that’s cancer. You never go into business, necessarily, for that reason as a CEO, but it sure is nice to do when you walk through the door and you know that everyone on your team will deliver a product and a service that benefits patients worldwide and puts doctors in a hero’s position,” Carnell said.
Carnell also took steps to shift the culture of the company, changing out 75% of the leadership team and half of the board. This year, Perseonissued guidance for sales of $3.5 million to $5 million, with gross margins of 65% to 75%.
Even with the hard work to reshape it, the company has had a rocky path. Earlier this month, it flirted with delisting by Nasdaq, but managed to bring in enough interest from investors to raise $4.3 million to avoid the jam.
Carnell said the road ahead wouldn’t be simple, for Perseon or any microcap medical device firm. Navigating FDA requirements takes longer, and issues with reimbursements are harder to handle than before, but he said he’s still optimistic.
“I just think it’s a fascinating area to work in. From my standpoint, these are just table stakes if you’re going to run a medical device company – learning how to put a good team together, a good strategy and learning how to overcome the necessary nuances of running a medical device company,” Carnell said.
Carnell said he hopes to expand Perseon’s microwave ablation technology from its current indication for stage 4 treatments to cover all stages. He claims the energy-based ablation is superior to radiofrequency, cryo and other forms of ablation that exist on the market today and is more affordable than the competition.
“Energy ablation, particularly microwave, is really an incredibly powerful tool in helping physicians fight cancer. I think what you’ll see from us and others is expansion into new organs, tumors and a blue sky opportunity to give them better treatment than anyone recognizes. In 5 years, if we’re doing a follow up with MassDevice, it’ll be a no-brainer that physicians go to microwave quickly, and see it as the safe and effective tool it is,” Carnell said.
And though it’s been a lot of hard work, according to Carnell, he’s enjoyed being at the reins for the company’s turnaround.
“It’s been a lot of fun, helping to reshape the company and finally putting it in a position to take advantage of the growth opportunity in front of us,” Carnell said".
What really Caught my eye,there is no other Biotech company trading under $5m Cap that FDA granted the company to market it's one-of-a-kind product and they marketing it right now.not to mention the huge increase on sales growing rate per last 10Q(sales increased 117%)..Get ready for AQXP 's type move.imo
The cheapest biotech NASDAQ company,but still solid, Especially after recent developments:
per 10Q: Assets/debt ratio about 2-solid. this is before recent offering."In connection with the closing of the Company’s registered offering of common stock and warrants on August 4, 2015, the Company received net proceeds of approximately $4.3 million".The Company believes that with the addition of these net proceeds it is now in compliance with the Stockholders' Equity Rule as of the date of this Current Report on Form 8-K. way over the minimum required($2.5m) by Listing Rule 5550(b)(1).
Based on Risks/Rewards, i find this very interesting due to the very low and rare cap,The MicroThermX® sales growing rate(117%!,check below the numbers) and the fact that "The U.S. Food and Drug Administration (FDA) granted the company a 510(k) clearance to market the MicroThermX for ablation of soft tissue".
The company owns eight non-expired patents in the United States related to certain components or technology of its ablation and hyperthermia systems. The company has one patent license from Duke University. 11 new U.S. patent applications have been published in theUnited States, and 1 foreign patent is issued and others are pending. A total of 29 U.S. patents have been issued to the company.Government Regulation The company’s products sold in the United States are subject to the Federal Food, Drug, and Cosmetic Act (FDCA), as implemented and enforced by the FDA. Certain of the company’s products sold in the United States require FDA clearance to market under Section 510(k) of the FDCA. History The company was incorporated under the laws of the state of Utah in 1978 and was reincorporated in the state of Delaware in 1986. It was formerly known as BSD Medical Corporation and changed its name to Perseon Corporation in 2015.
Mr. Carnell brings a successful 20+year track record of building companies and creating shareholder value. He recently served as an advisor to Covidien as executive in residence. From 2011-2014 he was President, Chief Executive and Chairman of myoscience, inc., a silicon valley based medical device company specializing in using cold to treat peripheral nerve conditions in pain and aesthetics. From 2005-2011, Clint was a key member of the executive team responsible for the turnaround of Thermage, Inc. including a successful IPO and responsibility for the integration of Reliant to create Solta Medical, Inc. as Chief Operating Officer. Solta later sold to Valeant Pharmaceuticals for 280 million dollars. Clint holds a Bachelor of Arts degree from Duke University.
Mr. Barth has decades of experience managing all aspects of the financial responsibilities of private and public medical device and biotech companies. Upon joining Perseon in 2013 he assumed the roles of Chief Financial Officer and Corporate Secretary. Throughout his career he played critical roles in completing several equity, debt, and merger transactions. Bill earned a Bachelor of Science in Accounting from Weber State University.
In 2015 Mr. Beckham joined Perseon as Vice President of Global Sales after accomplished careers with Solta Medical as Vice President of Sales, Americas and with Lifecore Biomedical as Vice President, Sales and Marketing. He has spent more than twenty years working with physicians to integrate new technologies into their practices. His sales leadership acumen and discipline situate our global teams to tout energy ablation. Ben received his BBA in Marketing from University of North Texas.
Perseon appointed Ms. Hoglin as Vice President ofGlobal Marketing in 2015 to capitalize on her marketing skills and medical device knowledge from years of experience with companies such as Edwards Lifesciences, CR Bard, Myriad Genetics, and 3M. She integrates voice of customer and market to all aspects of strategy development, product development, and commercialization.Jennifer earned a BA in Anthropology from TheColorado College and later an MBA from Olin School of Business at Washington University in St. Louis.
Brian A. Meltzer, M.D. joined Perseon in 2015 as Chief Medical Officer and Vice President of Business Development. His clinical knowledge from his years at Memorial Sloan-Kettering Cancer Center as well as his business experience in strategic innovation and new growth opportunities with Purdue Pharma, Johnson & Johnson, and Janssen Healthcare Innovation provide a nice combination that contribute to Perseon being the leader in energy ablation. Brian completed his internship and residency with Internal Medicine, and fellowship in gastroenterology at New York Hospital-Cornell Medical Center. He holds an MBA in Health Care Administration from Baruch College, City University of New York; an M.D. in Medicine from State University of New York Upstate Medical University; and a B.S. in Biomedical Science from City University of New York.
Mr. Turnlund was appointed Vice President of Research & Development in 2015. His career of over 25 years of experience with both medical device start-ups and Fortune 500 companies gives him the knowledge and respect to lead engineering teams in translating customer and market needs into marketable devices. Todd earned an undergraduate degree in Mechanical Engineering from University of California at Santa Barbara. Later, he earned an MBA from Santa Clara University.
Buy(P) / Sell(S) | P/S date | Filed Date | Company | Symbol | Insider | Relationship | Share Amt. | Unit Price | Total Proceeds | Shares Owned | Return(1m) | Details |
P | 2015-08-04 | 2015-08-05 18:29:03 | Perseon Corp | PRSN | Turnlund Todd | officer (VP Engineering) | 50,000 | $0.88 | $44,000.00 | 50,000 | N/A | view |
P | 2015-08-04 | 2015-08-05 18:16:31 | Perseon Corp | PRSN | VITULLI PETER | director | 58,000 | $0.88 | $51,040.00 | 58,188 | N/A | view |
P | 2015-08-04 | 2015-08-05 18:12:48 | Perseon Corp | PRSN | STEWART STEVEN G | director | 5,000 | $0.88 | $4,400.00 | 27,572 | N/A | view |
P | 2015-08-04 | 2015-08-05 18:11:33 | Perseon Corp | PRSN | McQuay Timothy C | director | 12,000 | $0.88 | $10,560.00 | 33,910 | N/A | view |
P | 2015-08-04 | 2015-08-05 18:10:05 | Perseon Corp | PRSN | Meltzer Brian A. | officer (Chief Medical Officer) | 1,000 | $0.88 | $880.00 | 1,000 | N/A | view |
P | 2015-08-04 | 2015-08-05 18:07:59 | Perseon Corp | PRSN | Carnell Clint | CEO | 29,000 | $0.88 | $25,520.00 | 29,000 | N/A | view |
View Transactions for Insiders & Institutional Holders Value shown is computed using the security's price on the report date given. Currency in USD. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
jhoglin@perseonmedical.com
1+(801)972-5555
On April 11, 2015 I posted my blog for the first time. We had just set up the office in a portion of the old BSD Medical building and we seem to be moving at the speed of light. It was our first week in business and I complained about the lack of staplers.
Start-ups are awesome.
Pyrexar Medical was formed to take on the fight against cancer. We purchased the Hyperthermia product line from BSD Medical in April 2015. Our plan is to support the existing BSD-500 and BSD-2000 customers, continue to make product improvements, support the growth of Thermal Oncology and spread the word about this amazing cancer therapy.
33 years experience designing and building hyperthermia products for Oncology departments, research organizations and leading universities.
Level 1 Clinical evidence that demonstrates howHyperthermia makes a significant increase in cancer response rates.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |